Skip to main content


Keynote speaker

Keynote address: History of Y-90 by Dr. Riad Salem, MD, MBA, FSIR
Thursday, October 6 | 4 - 4:30 p.m.

Upload Image
Riad Salem, MD, MBA, FSIR, is a professor of radiology, surgery and medicine, vice-chair, image-guided therapy and section chief, interventional radiology in the department of radiology at Northwestern University in Chicago and recipient of the 2022 Annual Dr. Charles T. Dotter Lecture. A graduate of McGill University in Montreal, Dr. Salem was the recipient of the Wood Gold Medal, as well as the J. Francis Award in Internal Medicine. He completed his residency in Washington DC, before completing a fellowship in interventional radiology (University of Pennsylvania), while additionally obtaining a Master’s in Business Administration (Finance). He is a member of Alpha Omega Alpha medical honor society and a Fellow of the Society of Interventional Radiology. He has delivered close to 800 lectures nationally and internationally and written extensively on the subject of interventional oncology and TIPS, with over 370 publications, 28,000 citations, and an h index of 92. His current research focuses on advances in minimally invasive therapies for HCC and CRC, complex trans-splenic TIPS in patients with porto-systemic thrombosis, as well as prostate artery embolization. He serves as global PI of two, international, randomized phase III trials involving sorafenib +/- Y90 in HCC (STOP-HCC) and chemotherapy +/- Y90 in CRC (EPOCH); EPOCH was the first large-scale RCT to meet its endpoints in the field of interventional oncology. Dr. Salem was also the lead investigator in LEGACY, the pivotal trial that lead to the FDA’s first PMA device approval. In 2017, he was the recipient of the SIR Foundation Leaders in Innovation Award.
Back to Top